Articles tagged with: Actimid

News»

[ by | Dec 7, 2010 3:37 pm | 2 Comments ]
Pomalidomide Shows Promising Results For Multiple Myeloma Patients Resistant To Revlimid And Velcade (ASH 2010)

Pomalidomide has demonstrated efficacy in heavily pre-treated multiple myeloma patients who have been treated with – or are even refractory to – Revlimid and Velcade.

Three studies of the use of pomalidomide (Pomalyst) in relapsed and refractory multiple myeloma patients were presented yesterday at the American Society of Hematology annual meeting in Orlando.

Pomalidomide, which is being developed by the pharmaceutical company Celgene, is an immunomodulatory agent that induces the immune system to destroy myeloma cells. It belongs to the same class of drugs as Revlimid (lenalidomide) and thalidomide (Thalomid). …

Read the full story »

News»

[ by | Feb 23, 2010 3:32 pm | 9 Comments ]
The Top Myeloma Research Of 2009

The year 2009 brought a lot of new and ex­cit­ing ad­vancements in the field of mul­ti­ple myeloma. Over the course of 2009, The Myeloma Beacon covered more than 100 im­por­tant myeloma-related stud­ies.

To highlight the most im­por­tant of these stud­ies, the Myeloma Beacon surveyed lead­ing physicians and re­searchers in the field. These physicians and re­searchers were asked to name the three peer reviewed journal articles pub­lished in 2009 and the three conference abstracts from 2009 that have the most im­por­tant findings or implications relating to mul­ti­ple myeloma.

The top three journal …

Read the full story »

News, Resources»

[ by | Jan 21, 2010 9:47 am | Comments Off ]
Thought Leader Perspective: Dr. Robert Kyle On Myeloma Treatments Requiring Further Study

Dr. Robert Kyle, a leading myeloma physician, researcher, and professor at the Mayo Clinic, spoke with The Myeloma Beacon about his approach to treating multiple myeloma patients; participation in clinical trials; many of the key issues for myeloma patients and physicians, including conventional and alternative treatment options; and the future of personalized medicine.

This article is the second part of a two-part series based on the Beacon’s conversations with Dr. Kyle. It will cover the role of clinical trials and key issues in the treatment of multiple myeloma as well as promising …

Read the full story »

News»

[ by | Nov 23, 2009 4:18 pm | 3 Comments ]
Single-Agent Actimid And Combination Actimid-Dexamethasone Regimens Are Promising Treatments For Relapsed Myeloma (ASH 2009)

At the upcoming meeting of the American Society of Hematology (ASH), there will be several presentations about Actimid (pomalidomide). Actimid, a new drug being developed by Celgene Corporation as a treatment for multiple myeloma, is a molecular derivative of thalidomide (Thalomid).

Actimid As A Combination Therapy With Dexamethasone

One of the ASH presentations will show that the combination regimen of Actimid and low-dose dexamethasone (Decadron) is an effective treatment for relapsed multiple myeloma.

Actimid was tested in combination with dexamethasone in 34 patients with relapsed myeloma following therapy with

Read the full story »

News»

[ by | Oct 14, 2009 9:29 am | Comments Off ]
New Directory Could Assist In Myeloma Treatment

Researchers at St George’s, University of London have developed a new directory that could lead to quicker and more targeted treatment for multiple myeloma and other cancer patients.

The directory identifies 40,000 genes that can cause cancer and lists the effects on each gene by three drugs used in the treatment of multiple myeloma.

The three drugs included in the directory are thalidomide (Thalomid), Revlimid (lenalidomide), and Actimid (pomalidomide, CC-4047). Both thalidomide and Revlimid are approved for the treatment of multiple myeloma. Actimid is still being tested for multiple …

Read the full story »

News»

[ by | Sep 4, 2009 9:55 pm | One Comment ]
Combination Actimid And Dexamethasone Regimen Is Promising For Relapsed And Refractory Myeloma Patients

The Journal of Clinical Oncology has reported that a combination regimen of Actimid (pomalidomide) and low-dose dexamethasone (Decadron) in a Phase 2 clinical trial was highly effective in the treatment of relapsed and refractory multiple myeloma patients.

Actimid belongs to a class of therapeutic agents called immunomodulatory drugs (IMiDs), which are molecular analogs of thalidomide (Thalomid). Thalidomide acts on myeloma tumors by inhibiting the growth of new blood vessels. In addition to this mechanism, IMiDs prevent the development of abnormal tissue masses called neoplasms and induce programmed cell death. …

Read the full story »

News»

[ by | Mar 15, 2009 8:56 pm | Comments Off ]

A num­ber of new drugs are on the horizon for re­lapsed and re­frac­tory patients, as discussed by physicians at the 2009 Inter­na­tional Myeloma Workshop (IMW). The dis­cus­sion covered drugs in all stages of devel­op­ment, from those still undergoing initial lab testing to ones already in inter­na­tional clin­i­cal trials.

Overall re­spon­siveness to treat­ment has im­proved dramatically with the recent in­tro­duc­tion of more potent agents such as Revlimid (lena­lido­mide) and Velcade (bor­tez­o­mib). Doctors are now testing com­bi­na­tions of these two drugs with newer pharma­ceu­ticals. Of the two, Velcade has been …

Read the full story »